Q J Med 2000; 93: 433-439
© 2000 Association of Physicians
Intravenous immunoglobulin for ANCA-associated systemic vasculitis with persistent disease activity
1 From the Division of Renal Medicine, St George's Hospital Medical School and Renal Unit, St Helier Hospital, London, 2 Department of Immunology, John Radcliffe Hospital, Oxford, 3 Department of Nephrology, Queen Elizabeth Hospital, Birmingham, 4 Department of Immunology, Leeds General Infirmary, 5 Department of Nephrology, Hope Hospital, Salford, 6 Department of Rheumatology, Norfolk and Norwich Hospital and 7 Department of Medicine, School of Clinical Medicine, Cambridge, UK
Received 17 September 1999 and in revised form 15 May 2000
Intravenous immunoglobulin (IVIg) is a potential alternative treatment for anti-neutrophil cytoplasm antibody (ANCA)-associated systemic vasculitis (AASV) with less toxicity than conventional immunosuppressive agents. This randomized, placebo-controlled trial aimed to investigate the efficacy of a single course of IVIg (total dose 2 g/kg) in previously-treated AASV with persistent disease activity in whom there was an intention to escalate therapy. Vasculitic activity was monitored by the Birmingham vasculitis activity score (BVAS), C-reactive protein (CRP) and ANCA levels. Treatment response was defined as a reduction in BVAS of more than 50% after 3 months, and there was an intention to keep doses of concurrent immunosuppressive drugs unchanged during this period; follow-up continued to 12 months. Seventeen patients were randomized to receive IVIg and 17 to receive placebo. Treatment responses were found in 14/17 and 6/17 of the IVIg and placebo groups, respectively (p=0.015, OR 8.56, 95%CI 1.74–42.2). Following infusion of trial medication, greater falls in CRP were seen at 2 weeks (p=0.02) and 1 month (p=0.04) in the IVIg group. No differences were observed between ANCA levels or cumulative exposure to immunosuppressive drugs, and after 3 months there were no differences in CRP levels or disease activity between the IVIg and placebo groups. Seventeen adverse effects occurred after IVIg and six after placebo: they were mostly mild, although reversible rises in serum creatinine occurred in four from the IVIg group. A single course of IVIg reduced disease activity in persistent AASV, but this effect was not maintained beyond 3 months; mild, reversible side-effects following IVIg were frequent. IVIg is an alternative treatment for AASV with persistent disease activity after standard therapy.
Address correspondence to Dr D.R.W. Jayne, Division of Renal Medicine, St George's Hospital Medical School, London SW17 0RE. e-mail: djayne{at}sghms.ac.uk
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C Mukhtyar, R Lee, D Brown, D Carruthers, B Dasgupta, S Dubey, O Flossmann, C Hall, J Hollywood, D Jayne, et al. Modification and validation of the Birmingham Vasculitis Activity Score (version 3) Ann Rheum Dis, December 1, 2009; 68(12): 1827 - 1832. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. A. Gomez-Puerta, J. Hernandez-Rodriguez, A. Lopez-Soto, and X. Bosch Antineutrophil Cytoplasmic Antibody-Associated Vasculitides and Respiratory Disease Chest, October 1, 2009; 136(4): 1101 - 1111. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C Mukhtyar, L Guillevin, M C Cid, B Dasgupta, K de Groot, W Gross, T Hauser, B Hellmich, D Jayne, C G M Kallenberg, et al. EULAR recommendations for the management of primary small and medium vessel vasculitis Ann Rheum Dis, March 1, 2009; 68(3): 310 - 317. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 O Flossmann, P Bacon, K de Groot, D Jayne, N Rasmussen, P Seo, K Westman, and R Luqmani Development of comprehensive disease assessment in systemic vasculitis Postgrad. Med. J., March 1, 2008; 84(989): 143 - 152. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Bosch, A. Guilabert, G. Espinosa, and E. Mirapeix Treatment of Antineutrophil Cytoplasmic Antibody Associated Vasculitis: A Systematic Review JAMA, August 8, 2007; 298(6): 655 - 669. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Jayne Leflunomide versus methotrexate in Wegener's granulomatosis Rheumatology, July 1, 2007; 46(7): 1047 - 1048. [Full Text] [PDF]
|
|
|
|
|
|
P. M Stassen, J. W. Cohen Tervaert, and C. A Stegeman Induction of remission in active anti-neutrophil cytoplasmic antibody-associated vasculitis with mycophenolate mofetil in patients who cannot be treated with cyclophosphamide Ann Rheum Dis, June 1, 2007; 66(6): 798 - 802. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. S Zandi and A. J Coles Notes on the kidney and its diseases for the neurologist J. Neurol. Neurosurg. Psychiatry, May 1, 2007; 78(5): 444 - 449. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. M Gurcan and A R. Ahmed Efficacy of Various Intravenous Immunoglobulin Therapy Protocols in Autoimmune and Chronic Inflammatory Disorders Ann. Pharmacother., May 1, 2007; 41(5): 812 - 823. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Hellmich, O. Flossmann, W. L Gross, P. Bacon, J. Willem Cohen-Tervaert, L. Guillevin, D. Jayne, A. Mahr, P. A Merkel, H. Raspe, et al. EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis Ann Rheum Dis, May 1, 2007; 66(5): 605 - 617. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Flossmann, P. Bacon, K. de Groot, D. Jayne, N. Rasmussen, P. Seo, K. Westman, and R. Luqmani Development of comprehensive disease assessment in systemic vasculitis Ann Rheum Dis, March 1, 2007; 66(3): 283 - 292. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R Foster, E Rosenthal, S Marques, P Vounotrypidis, S Sangle, and D D'Cruz Primary systemic vasculitis: treatment of difficult cases Lupus, March 1, 2006; 15(3): 143 - 147. [Abstract] [PDF]
|
|
|
|
 |
|
 M. A. Little, G. Bhangal, C. L. Smyth, M. T. Nakada, H. T. Cook, S. Nourshargh, and C. D. Pusey Therapeutic Effect of Anti-TNF-{alpha} Antibodies in an Experimental Model of Anti-Neutrophil Cytoplasm Antibody-Associated Systemic Vasculitis J. Am. Soc. Nephrol., January 1, 2006; 17(1): 160 - 169. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. H. Ahmed, T. Aziz, J. Cochran, and K. Highland Use of Extracorporeal Membrane Oxygenation in a Patient With Diffuse Alveolar Hemorrhage Chest, July 1, 2004; 126(1): 305 - 309. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. H. Nachman and J. Martin Developments in the Immunotherapy of Glomerular Disease Journal of Pharmacy Practice, December 1, 2002; 15(6): 472 - 489. [Abstract] [PDF]
|
|
|
|
 |
|
 P. A. Schlesinger and J. W. Leatherman Rheumatology Am. J. Respir. Crit. Care Med., November 1, 2002; 166(9): 1161 - 1165. [Full Text] [PDF]
|
|
|
|
|
|
L. Kamesh, L. Harper, and C. O. S. Savage ANCA-Positive Vasculitis J. Am. Soc. Nephrol., July 1, 2002; 13(7): 1953 - 1960. [Full Text] [PDF]
|
|
|
|
|
|
C M Wiles, P Brown, H Chapel, R Guerrini, R A C Hughes, T D Martin, P McCrone, J Newsom-Davis, J Palace, J H Rees, et al. Intravenous immunoglobulin in neurological disease: a specialist review J. Neurol. Neurosurg. Psychiatry, April 1, 2002; 72(4): 440 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Pyne, M. Ehrenstein, and V. Morris The therapeutic uses of intravenous immunoglobulins in autoimmune rheumatic diseases Rheumatology, April 1, 2002; 41(4): 367 - 374. [Full Text] [PDF]
|
|
|
|
 |
|
 J. Levy New aspects in the management of ANCA-positive vasculitis Nephrol. Dial. Transplant., July 1, 2001; 16(7): 1314 - 1317. [Full Text] [PDF]
|
|